FMP
Lexicon Pharmaceuticals, Inc.
LXRX
NASDAQ
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
0.751 USD
0.0124 (1.65%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Michael Exton Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.lexpharma.comexchange
NASDAQ
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
CIK
0001062822
ISIN
US5288723027
CUSIP
528872302
Address
2445 Technology Forest Bouleva...
Phone
281 863 3000
Country
US
Employee
285
IPO Date
Apr 7, 2000
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
LXRX Financial Summary
CIK
0001062822
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
528872302
ISIN
US5288723027
Country
US
Price
0.75
Beta
1.24
Volume Avg.
4.2M
Market Cap
271.44M
Shares
-
52-Week
0.62-3.73
DCF
-0.39
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.01
P/B
-
Website
https://www.lexpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LXRX News
It looks like there's no news available.
